Maiwenn J Al

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2280906/publications.pdf

Version: 2024-02-01

74	3,143	186209	161767
papers	citations	28 h-index	54 g-index

76	76	76	4581
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients. PLoS ONE, 2022, 17, e0261940.	1.1	6
2	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. Drugs - Real World Outcomes, 2022, , 1.	0.7	0
3	Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. JMIR Cardio, 2022, 6, e31302.	0.7	1
4	Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. Value in Health, 2021, 24, 1435-1445.	0.1	3
5	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. European Journal of Health Economics, 2020, 21, 153-164.	1.4	30
6	Impact of hospitalisation on health-related quality of life in patients with chronic heart failure. Health and Quality of Life Outcomes, 2020, 18, 262.	1.0	14
7	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. Frontiers in Public Health, 2020, 8, 612410.	1.3	9
8	Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2020, 24, 1-220.	1.3	12
9	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy, 2019, 17, 883-893.	1.0	15
10	TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. Pharmacoeconomics, 2019, 37, 1391-1408.	1.7	33
11	First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis . OncoTargets and Therapy, 2019, Volume 12, 1413-1421.	1.0	51
12	Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 141-153.	1.7	8
13	The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 2018, 19, 31.	2.9	9
14	Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 145-159.	1.7	10
15	Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 161-175.	0.7	4
16	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	1.1	9
17	Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. Pharmacoeconomics, 2018, 36, 105-113.	1.7	5
18	Cost Recommendation under Uncertainty in IQWiGâ€™s Efficiency Frontier Framework. Medical Decision Making, 2017, 37, 162-172.	1.2	2

#	Article	IF	Citations
19	Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology, 2017, 56, 777-786.	0.9	28
20	A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. Value in Health, 2017, 20, 1041-1047.	0.1	10
21	Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 1211-1221.	1.7	21
22	Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. PLoS ONE, 2017, 12, e0171292.	1.1	0
23	Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2017, 21, 1-234.	1.3	59
24	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. Arthritis Care and Research, 2016, 68, 308-317.	1.5	27
25	Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics, 2016, 34, 315-322.	1.7	19
26	The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling. Applied Health Economics and Health Policy, 2016, 14, 129-133.	1.0	33
27	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology, 2016, 55, 809-816.	0.9	21
28	Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics, 2016, 34, 23-31.	1.7	2
29	Integrated sensor-augmented pump therapy systems [the MiniMedÂ® Paradigmâ„¢ Veo system and the Vibeâ„¢ and G4Â® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-252.	1.3	57
30	Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Management and Research, 2015, 7, 279.	0.9	8
31	Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. Value in Health, 2015, 18, 100-109.	0.1	4
32	Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-228.	1.3	230
33	Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-106.	1.3	74
34	The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-66.	1.3	25
35	A Choice That Matters?. Pharmacoeconomics, 2013, 31, 719-730.	1.7	5
36	The Role of Value-of-Information Analysis in a Health Care Research Priority Setting. Medical Decision Making, 2013, 33, 472-489.	1.2	7

#	Article	IF	Citations
37	Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2013, 132, 353-360.e2.	1.5	263
38	Cost-effectiveness of tiotropiumversussalmeterol: the POET-COPD trial. European Respiratory Journal, 2013, 41, 556-564.	3.1	9
39	Cost-Effectiveness Acceptability Curves Revisited. Pharmacoeconomics, 2013, 31, 93-100.	1.7	28
40	Continuous versus Intermittent Data Collection of Health Care Utilization. Medical Decision Making, 2013, 33, 998-1008.	1.2	26
41	Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme. BMC Health Services Research, 2013, 13, 370.	0.9	6
42	Comparing Methods of Data Synthesis. Pharmacoeconomics, 2011, 29, 239-250.	1.7	8
43	Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. Value in Health, 2011, 14, 1039-1047.	0.1	30
44	Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. Journal of Medical Economics, 2011, 14, 245-252.	1.0	2
45	Association between lung function and exacerbation frequency in patients with COPD. International Journal of COPD, 2010, 5, 435.	0.9	79
46	Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Critical Care, 2010, 14, R195.	2.5	31
47	The cost utility of solifenacin in the treatment of overactive bladder. International Urology and Nephrology, 2009, 41, 293-298.	0.6	12
48	The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value in Health, 2009, 12, 1086-1099.	0.1	69
49	Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine, 2009, 27, 2531-2532.	1.7	5
50	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer, 2008, 112, 1337-1344.	2.0	44
51	Uncertainty in Decision-Making: Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People. Value in Health, 2008, 11, 424-434.	0.1	14
52	Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands. Value in Health, 2008, 11, 589-599.	0.1	15
53	Economic Valuation of Informal Care: Conjoint Analysis Applied in a Heterogeneous Population of Informal Caregivers. Value in Health, 2008, 11, 1041-1050.	0.1	33
54	Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. Value in Health, 2008, 11, 1070-1080.	0.1	52

#	Article	IF	Citations
55	The cost-utility of rotavirus vaccination with Rotarixâ„¢ (RIX4414) in the Netherlands. Vaccine, 2008, 26, 1118-1127.	1.7	69
56	Review of A Large Clinical Series: A Microcosting Study of Intensive Care Unit Stay in the Netherlands. Journal of Intensive Care Medicine, 2008, 23, 250-257.	1.3	38
57	Cost-utility of brief psychological treatment for depression and anxiety. British Journal of Psychiatry, 2006, 188, 323-329.	1.7	54
58	Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. Social Science and Medicine, 2005, 61, 1342-1355.	1.8	63
59	The analysis of incomplete cost data due to dropout. Health Economics (United Kingdom), 2005, 14, 763-776.	0.8	88
60	Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Economics (United Kingdom), 2005, 14, 655-667.	0.8	31
61	Portfolio Theory and Cost-Effectiveness Analysis: A Further Discussion. Value in Health, 2004, 7, 595-601.	0.1	6
62	A Risk-Adjusted Approach to Comparing the Return on Investment in Health Care Programs. International Journal of Health Care Finance and Economics, 2004, 4, 199-210.	1.2	8
63	Decision makersâ€™ views on health care objectives and budget constraints: results from a pilot study. Health Policy, 2004, 70, 33-48.	1.4	34
64	Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations. Social Science and Medicine, 2004, 58, 1853-1855.	1.8	10
65	Revisiting the decision rule of costâ€“effectiveness analysis under certainty and uncertainty. Social Science and Medicine, 2003, 57, 969-974.	1.8	26
66	Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Social Science and Medicine, 2003, 57, 2207-2215.	1.8	45
67	Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting. Pharmacoeconomics, 2003, 21, 1103-1112.	1.7	54
68	Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity. Pharmacoeconomics, 2001, 19, 17-32.	1.7	34
69	A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. Health Economics (United Kingdom), 2000, 9, 599-609.	0.8	31
70	Sample size calculation in economic evaluations. , 1998, 7, 327-335.		47
71	Technology Assessment of the Dutch Lung Transplantation Program. International Journal of Technology Assessment in Health Care, 1998, 14, 344-356.	0.2	37
72	Cost-effectiveness of Lung Transplantation in the Netherlands. Chest, 1998, 113, 124-130.	0.4	52

#	Article	IF	Citations
73	The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis. Pharmacoeconomics, 1996, 10, 141-151.	1.7	13
74	Costs, effects and C/E-ratios alongside a clinical trial. Health Economics (United Kingdom), 1994, 3, 309-319.	0.8	825